News

TScan Therapeutics Engages Investors at Key Upcoming Events

TScan Therapeutics Engages Investors at Key Upcoming Events

TScan Therapeutics Engages Investors at Key Upcoming Events

TScan Therapeutics, Inc. (Nasdaq: TCRX), a pioneering clinical-stage biotechnology company, is excited to announce its participation in a series of significant investor conferences. Focused on the development of T cell receptor (TCR)-engineered T cell (TCR-T) therapies, TScan is dedicated to offering groundbreaking solutions for cancer treatment.

What to Expect from Upcoming Conferences

At the Morgan Stanley 23rd Annual Global Healthcare Conference, set for September 9, 2025, a fireside chat will take place at the Sheraton New York Times Square at 5:35 p.m. ET. This event will provide an important platform for discussions surrounding the future of TCR-T therapies.

Details of Additional Conference Participation

Another major highlight will be at the H.C. Wainwright 27th Annual Global Investment Conference on September 10, 2025, at the Lotte New York Palace Hotel, where TScan will present at 9:00 a.m. ET. These conferences are pivotal moments for TScan to connect with investors and share their latest advancements.

Accessing Presentations and Webcasts

For those unable to attend in person, TScan Therapeutics will make webcasts of these events available. Interested parties can find them under the "Events and Presentations" section of the company’s website, where archived replays will also be accessible for 90 days post-event. This ensures that information about TScan's progress and innovations can reach a wider audience.

Insight into TScan Therapeutics

TScan is committed to advancing the field of oncology with its innovative TCR-T therapies. The company’s lead candidates are currently under development, aimed at treating hematologic malignancies while preventing relapse following allogeneic hematopoietic cell transplantation. This aligns perfectly with the company’s overarching goal to provide customized solutions for patients.

The Importance of the ImmunoBank

One of the key assets of TScan is its ImmunoBank, a comprehensive repository of therapeutic TCRs. These TCRs are tailored to recognize a diverse range of targets associated with multiple HLA types, enabling TScan to offer customized multiplex TCR-T therapies for various cancer types. The ongoing trials, including the ALLOHA Phase 1 heme trial and the PLEXI-T Phase 1 solid tumor trial, emphasize TScan's dedication to innovative cancer treatments.

Contact Information for Investor Relations

For more information, investors can reach out to TScan Therapeutics through their VP of Investor Relations, Heather Savelle, at 857-399-9840 or via email. Additionally, Melissa Forst from Argot Partners is available for inquiries. Their dedication to transparency keeps investors well-informed about company initiatives and advancements.

Frequently Asked Questions

1. What is TScan Therapeutics known for?

TScan Therapeutics is recognized for its development of TCR-engineered T cell therapies aimed at treating cancer patients.

2. When are the upcoming investor conferences?

Key conferences will take place on September 9 and September 10, 2025, in New York City.

3. How can I access the webcasts from the conferences?

Webcasts will be available on the "Events and Presentations" section of TScan's website for 90 days after the events.

4. What is the ImmunoBank?

The ImmunoBank is TScan's repository of therapeutic TCRs that allows for customized TCR-T therapies for various cancer types.

5. Who can I contact for more information about TScan?

For additional details, you can contact Heather Savelle at TScan or Melissa Forst at Argot Partners.

About The Author

About Investors Hangout

Investors Hangout is a leading online stock forum for financial discussion and learning, offering a wide range of free tools and resources. It draws in traders of all levels, who exchange market knowledge, investigate trading tactics, and keep an eye on industry developments in real time. Featuring financial articles, stock message boards, quotes, charts, company profiles, and live news updates. Through cooperative learning and a wealth of informational resources, it helps users from novices creating their first portfolios to experts honing their techniques. Join Investors Hangout today: https://investorshangout.com/

The content of this article is based on factual, publicly available information and does not represent legal, financial, or investment advice. Investors Hangout does not offer financial advice, and the author is not a licensed financial advisor. Consult a qualified advisor before making any financial or investment decisions based on this article. This article should not be considered advice to purchase, sell, or hold any securities or other investments. If any of the material provided here is inaccurate, please contact us for corrections.

Top 10 Most Recent News Articles

Novo's CagriSema Trial Shows Promising Obesity Results

Updated Category News Views 371

Novo's Latest Weight Loss Gamble Well, look what we have here. Novo Nordisk is shaking up the obesity treatment scene with some bold numbers from their REDEFINE 9 trial. The investigational CagriSema combo of amylin analog and GLP-1 receptor agonist has churned out an eyeball-popping near 21% weight loss. For context, we're staring down the barrel of numbers far meatier...

Continue Reading
Servier's Data on Tovorafenib Shows Promise in pLGG

Updated Category News Views 409

New Light on a Critical Challenge Talk about a fight in the dark. Pediatric low-grade glioma (pLGG) is a menace that families dread, an uphill battle with odds that feel relentless. Enter Servier and its four-year updated data on OJEMDA® (tovorafenib), a beacon of hope for kids battling these tricky brain tumors. Results, presented at the SNO meeting, are fresh off the...

Continue Reading
CARsgen's CAR-T Breakthrough on China's Insurance List

Updated Category News Views 298

A Game Changer for CAR-T Therapies There's a breeze of optimism blowing from Shanghai these days—a rare sensation in this market of endless skirmishes. CARsgen Therapeutics Holdings Limited, a company entrenched in the development of cutting-edge CAR T-cell therapies, just notched a victory. They've announced that their CAR T-cell therapy product, satricabtagene...

Continue Reading
Lilly's Obesity Breakthroughs: A Step Beyond the Scale

Updated Category News Views 229

Pushing the Boundaries of Obesity Treatment Alright, let's cut through the noise and get to what really matters here. Eli Lilly is taking on obesity treatment like it's Clash of the Titans at this year's ObesityWeek 2026 in Washington, D.C. Forget just dropping pounds—Lilly wants to reshape how we think about obesity entirely. They're not just leaning into the scale,...

Continue Reading
WeaveGrid Powers EVConnectNC: Charging Incentives Launched

Updated Category News Views 177

Transforming Utilities with EVConnectNC In a fresh move by WeaveGrid, North Carolina's Electric Cooperatives have teamed up to roll out EVConnectNC. This innovative program aims to manage the burgeoning demand for electric vehicle (EV) charging in rural and suburban areas under North Carolina's cooperative umbrella. Think of it as a smart way to handle new loads without...

Continue Reading
WHO and RCSI Bahrain Join Forces on Health Initiatives

Updated Category News Views 28

Forging a Healthier Pathway In a world where healthcare challenges rise faster than my blood pressure during a stock market crash, the World Health Organization (WHO) and the Royal College of Surgeons in Ireland (RCSI) – Medical University of Bahrain have inked a deal to tackle these issues head-on. The memorandum of understanding (MoU) signed on November 15, 2026,...

Continue Reading
Breakthrough T1D Pushes Global T1D Awareness Forward

Updated Category News Views 214

Shining a Light on T1D with Global Efforts In a world where a change in lifestyle can happen at the drop of a hat, Breakthrough T1D is making waves by expanding their global "See T1D" campaign in honor of World Diabetes Day. This isn't your run-of-the-mill awareness push—this is about propelling an understanding of what life truly entails for those living with type 1...

Continue Reading
EZaccessMD Data Breach: Class Action Lawsuit Looms

Updated Category News Views 180

Data breaches are the bogeyman no one wants lurking in the shadows, and when it’s your personal info at stake, folks rightfully squirm. This recent fiasco at EZaccessMD is one of those unsettling incidents. The word on the street isn't pretty: sensitive medical data has slipped through the cracks, leaving Edelson Lechtzin LLP, a heavyweight in class action maneuvers, to...

Continue Reading
Retirement Dreams Dashed: 61% Withdraw Early

Updated Category News Views 298

Retirement Caught in the Crosshairs Just when you think the path to retirement might clear up, life slaps down older workers with economic reality. A recent LiveCareer survey underscores this financial mess, revealing that 61% of those 50 and older are raiding their own retirement funds to make ends meet. It's enough to make one's head spin. Inflation: The Unwanted Guest...

Continue Reading
Luvme Hair Offers Wig Variety for Winter Fashion

Updated Category News Views 353

Adding Flair to Winter Looks A style kick-off from the fashion world: Luvme Hair is flipping the table on winter wardrobes with a new collection of wigs. As the weather ramps up the need for thick coats and cumbersome layers, these long hairstyles offer a little extra swing, bringing dimension into the mix. Fancy a change from traditional winter hibernation? Here’s what...

Continue Reading

Top 5 Most Recently Viewed Articles

Waymo and Hyundai Unite for a Revolutionary Ride-Hailing Future

Updated Category News Views 123

Waymo and Hyundai Join Forces for Autonomous Innovations Recently, Hyundai Motor Company and Waymo, a leader under the umbrella of Alphabet Inc., outlined an exciting multi-year partnership aimed at revolutionizing the autonomous taxi scene. Central to this collaboration is the integration of Waymo's advanced sixth-generation autonomous technology, widely recognized as...

Continue Reading
Klépierre Announces Update on Voting Rights and Shares

Updated Category News Views 158

Klépierre Shares and Voting Rights Overview In a significant update regarding the total voting rights and shares, Klépierre, a renowned shopping mall leader in Europe, has disclosed vital information as of April 30, 2025. This information is crucial for current and potential investors as it sheds light on the company’s governance and shareholding structure. Current...

Continue Reading
Exciting New Volleyball Franchise to Debut in Minnesota

Updated Category News Views 253

New Franchise Spotlight: Minnesota Joins Major League Volleyball Major League Volleyball (MLV) is set to enhance its dynamic league with the addition of Minnesota as a franchise market. This exciting development will see Minnesota entering the competition in 2027, bringing the total number of teams in the league to 11. Ownership and Leadership Team The Minnesota franchise...

Continue Reading
Insights on Challenger Energy Group's Strategic Acquisition Plans

Updated Category News Views 161

Latest Developments in the Challenger Energy Acquisition Dear Fellow Shareholders, There’s an exciting journey unfolding for Challenger Energy Group plc as the company is taking significant strides towards a proposed all-share acquisition that holds the promise of redefining our strategic landscape. Just recently, Challenger and Sintana Energy announced the publication...

Continue Reading
Emboa Medical's Innovative Catheter Revolutionizes Stroke Treatment

Updated Category News Views 347

Revolutionizing Stroke Treatment with Innovative Technology Emboa Medical Inc., a pioneering medical device startup, is leading the charge in improving outcomes for stroke patients by developing a revolutionary catheter inspired by nature. The company’s creation, a novel microstructured catheter known as the TRAP (Thrombus Retrieval Aspiration Platform), utilizes...

Continue Reading